SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001725160-24-000163
Filing Date
2024-10-04
Accepted
2024-10-04 18:01:21
Documents
1
Period of Report
2024-10-04

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1728079274.html 4  
1 FORM 4 wk-form4_1728079274.xml 4 3473
  Complete submission text file 0001725160-24-000163.txt   5160
Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Issuer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ZENTALIS PHARMACEUTICALS, INC. 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address
Vultaggio Vincent (Reporting) CIK: 0002018766 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39263 | Film No.: 241355839